GT Biopharma, Inc.
GTBPHealthcare|Biotechnology|US
$4.42
-0.12 (-2.64%)
DCF Value
$27.76
Tangible Book / Share
$2.30
Cash / Share
$3.19
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07541573 GTB-5550 in Advanced Solid Tumors | Tri-specific Killer Engager, Solid Tumor | P1 | Recruiting | 175 | Open-label | GTB-5550 |
| NCT03214666 GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | P1P2 | Terminated | 12 | Open-label | GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II |